Hematology Frontier

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) will be held in Kumamoto, Japan, from September 24 to 27, 2025. One of the major…

Hematologic malignancies such as leukemia, lymphoma, and multiple myeloma remain among the most challenging cancers to treat due to high relapse rates and treatment resistance. Tumor necrosis factor-related apoptosis-inducing ligand…

Allogeneic stem cell transplantation (ASCT) is the most definitive curative strategy for patients with acute leukemia (AL), especially those with high relapse risk. Traditionally, the decision to proceed to transplant…

Primary vitreoretinal lymphoma (PVRL) is a rare but highly aggressive intraocular malignancy closely associated with primary central nervous system lymphoma (PCNSL). Characterized by vague symptoms and high rates of misdiagnosis,…

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid precursor cells. Cytarabine (Ara-C) remains a cornerstone of induction chemotherapy; however, primary and acquired resistance to Ara-C significantly limits its therapeutic efficacy. Emerging studies have suggested that immune checkpoint and receptor molecules may influence tumor chemosensitivity, yet the role of TREML2, a member of the TREM family, has remained largely unexplored in the AML context. This article, published in Blood Science, investigated TREML2 expression in AML and uncovered its role in modulating responsiveness to Ara-C.

ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess expectations surrounding NUTM1 fusion-positive leukemias and investigate the biological complexity behind treatment failure.

Essential thrombocythemia (ET) is a common myeloproliferative neoplasm characterized by elevated platelet counts, thrombotic and hemorrhagic events, and significantly impaired quality of life. At the 2025 European Hematology Association (EHA)…

The 2025 European Hematology Association (EHA) Annual Congress was successfully held from June 12 to 15 in Milan, Italy. Marking the 30th anniversary of the EHA, this year’s congress stood out as a major milestone, drawing over 15,000 experts and scholars from around the world with its global impact and groundbreaking research highlights. During the event, Oncology Frontier – Hematology Frontier had the privilege of speaking with Professor Martin Dreyling, Chair of the EHA 2025 Scientific Program Committee (SPC) and a professor at LMU Munich, to explore the most transformative scientific advances presented at the meeting.

At the 2025 Annual Congress of the European Hematology Association (EHA), the much-anticipated updated EHA-EMN clinical practice guidelines for multiple myeloma (MM) were officially released. Covering key areas such as diagnostic assessment, risk stratification, treatment pathways, and follow-up management, the new guidelines provide more forward-thinking and practical guidance for clinical implementation.

In the height of summer, Harbin—known as the “Ice City”—welcomed a gathering of scientific minds. From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The congress brought together top experts from China and abroad to discuss advancements in leukemia, lymphoma, multiple myeloma, and other hematologic diseases, spanning basic research, novel drug development, precision medicine, and clinical translation. Acute myeloid leukemia (AML) remains one of the most challenging diseases in clinical hematology, urgently requiring innovative breakthroughs. At the conference, Professor Xiaoyu Zhu from the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) presented exciting findings on “Basic and Translational Research on Double-Negative T Cells for AML Treatment.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhu further elaborated on the latest progress in this cutting-edge field.